Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Nokia | Digital Realty Trust | Moderna | |
|---|---|---|---|
| Moat rating | narrow The advantage is narrow and confined to one small unit. In the FY2025 20-F (filed 2026-03-05), Nokia Technologies turned EUR 1 501m of net sales into EUR 1 059m of operating profit (70.6%) while the group earned EUR 885m on EUR 19 889m (4.4%) — licensing out-earned the whole company on 7.5% of sales. Mobile Networks ran a 2.8% margin, down 270bps from 5.5% in 2024, against risk factors citing "equipment price erosion and aggressive price competition". Nokia Technologies net sales fell 22% from EUR 1 928m and operating profit 30% on 2024 catch-up, yet it is not eroding: over EUR 800m of contracted recurring revenue runs through 2030 and Technology Standards grew 12% cc in H1'26. | narrow The FY2025 10-K's own competitive record cuts both ways. Item 1 says a "high-quality, highly interconnected global portfolio such as ours could not be easily replicated today on a cost-competitive basis," yet Item 1A concedes that competitors have "significantly greater financial, marketing and other resources and more ready access to capital" and that as rivals keep developing space, "rental rates may be reduced or we may face delays in leasing." A durable advantage that its own filing says new supply can price against is bounded, not unassailable. | narrow The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. |
| Moat type | intangibles ip The advantage is standard-essential cellular patents, and it lives in one unit. Nokia Technologies conducts "cellular, multimedia and WiFi research and standardization, protects Nokia's innovation by securing patents" and "monetizes Nokia's innovation through patent licensing", across "more than 26 000 families, including over 8 000 essential to 5G" and "more than 250 licensees" including Apple, Samsung and Mercedes-Benz. It is not network effects or switching costs: customers "may also consolidate their supplier base to our disadvantage - all the way to a one-supplier model". From 1 January 2026 the unit reports as Technology Standards inside Mobile Infrastructure. | network effects Item 1 attributes the hard-to-replicate part of the portfolio to connectivity rather than to real estate: "the network density, interconnection infrastructure and connectivity-centric customers in certain of our data centers have led to the organic formation of densely connected data communities that are difficult for competitors to replicate." That community sits on over 232,000 cross connects in over 55 metros, so each network and cloud that lands makes the same building worth more to the next tenant. | intangibles ip The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." |
| Leadership | at parity Nokia is top-three almost everywhere and decisive only in slices. The 20-F reports that "Dell'Oro and Omdia ranked Nokia third in global Mobile RAN market share for the first three quarters", and Radio Networks is the largest single business unit (EUR 1 765m of EUR 4 815m group, Q2'26). It also holds #2 in global optical, #1 in IP edge routing and #1 in xPON OLT for a sixth year (Dell'Oro/Omdia Q3'25), while in data centers it competes "against large incumbent players" and calls expansion "challenging". 2025 segment sales were Network Infrastructure EUR 7 986m vs Mobile Networks EUR 7 806m; the Q2'26 6-K shows Optical +20%, IP +16% cc, AI & Cloud EUR 446m vs 220m, Radio +7%. | co leader Item 1 claims the title of "the largest global provider of cloud- and carrier-neutral data center, colocation and interconnection solutions," but the Competition section names Equinix and NTT as operators of properties "similar to ours in some of the same metropolitan areas," plus Global Switch and regional operators abroad — a shared top tier on the company's own telling, not a solitary one. | co leader The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." |
| Pricing power | weak Pricing power is weak at the consolidated grain, in the filing's own words. The 20-F risk factors describe a market "characterized by maturing industry technologies... equipment price erosion and aggressive price competition", customers "reverting to vendors to compensate" for their own unit-revenue erosion, and warn Nokia "may increasingly be required to agree to less favorable contractual terms in order to remain competitive". Group operating margin was 4.4% in 2025. This band covers equipment, ~92% of sales, not licensing, whose FRAND-bound royalties ran a 70.6% margin; supply-tight optical is our inference, not filing text. | strong FY2025 renewals signed re-priced upward in every bucket — +27.0% on greater-than-1 MW space ($146 to $186 per square foot), +4.6% on 0-1 MW ($268 to $280) and +43.0% on other ($49 to $71) — and MD&A expects average aggregate rental rates on 2026 renewals to be positive against the rates currently paid for the same space "on a GAAP basis and on a cash basis." On costs, the filing says utilities expense "is our largest expense category" and that "the vast majority of the expense is passed directly through to our customers," which it credits with significantly mitigating exposure to power-cost increases rather than removing it. The cap: Item 1A warns competitor development could still force rates down. | weak Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." |
| Summary | Nokia's moat is real but small and segment-bound. Per the FY2025 Form 20-F (filed 2026-03-05; Nokia files a 20-F, not a 10-K), the cellular SEP portfolio — 26 000+ patent families, 8 000+ declared essential to 5G, 250+ licensees, EUR 800m+ annual contracted recurring revenue through 2030 — produced a 70.6% operating margin on EUR 1 501m of sales and out-earned the entire group (EUR 885m). Everything else is competitive equipment: group operating margin 4.4%, Mobile Networks 2.8% (-270bps), with the filing's own risk factors describing price erosion, less favorable contract terms and customers consolidating "all the way to a one-supplier model". Rankings are per-line (#3 RAN, #2 optical, #1 IP edge routing, #1 xPON OLT; Dell'Oro/Omdia Q3'25), never company-wide. Q2/H1'26 figures come from the 23 Jul 2026 6-K: sec.gov/Archives/edgar/data/924613/000110465926086081/tm2621179d1_6k.htm | Digital Realty rents space, power and connectivity rather than compute: at 2025 year-end its portfolio held 310 data centers and roughly 57.6 million rentable square feet across more than 55 metros in over 30 countries, about 84.7% leased, serving more than 5,000 customers. Two different businesses sit inside that footprint. The greater-than-1 MW wholesale side is a capital-and-power race — 769 MW of projects underway with 64% pre-leased, and land that "could accommodate over 3,500 megawatts of additional data center capacity" — where the 10-K names Equinix, NTT, Global Switch and "various private operators" as rivals and warns that added supply can push rents down. The colocation and interconnection side is the defended half: over 232,000 cross connects and the "densely connected data communities" Item 1 says competitors cannot easily replicate, reinforced by contracts the filing describes as generally running 5-10+ years on large deployments and by improvements "installed at our customers' expense." FY2025 leasing supports that read — renewals signed re-priced +27.0% on greater-than-1 MW space and +4.6% on 0-1 MW — while customer concentration is the offsetting exposure, with the largest customer at roughly 11.7% of annualized recurring revenue. | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. |
| Chain position | — | Landlord to the AI stack — sells the space, power and interconnection that cloud, network and enterprise tenants run compute in (Oracle, IBM, Meta Platforms, AT&T, Comcast and Lumen are among the customers named in Item 1), with roughly 2.9 GW of total in-place IT capacity. | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | -0.01 at weight 0.20 · swarm bearish Editorial prior, not backtested. | +0.17 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm bearish Editorial prior, not backtested. |